Abstract
Leptin has emerged as a major regulator of body adiposity. The majority of humans with obesity have a resistance to leptin. Human and rodent studies indicate that the major cause of this resistance arises from an impaired ability of leptin to cross the blood-brain barrier, with lesser roles played by receptor and post-receptor defects. Evidence from baboons living in the wild is consistent with the hypothesis that during most of evolution serum levels of leptin were much lower than those currently considered normal. Leptin may have evolved to signal to the brain when caloric reserves were adequate to engage in reproductive and other behaviors not immediately concerned with acquisition of calories. The leptin transporter is a regulated system, with the rate of transport being increased by alpha-1 adrenergic agents and decreased by starvation. Impaired regulation of the transporter or impairments in transporter production could underlie the resistance caused by transporter defects. Evolutionary pressures would not have selected against such impairments if leptin levels were lower than those typically seen in Western society. A model that could explain how leptin transporter resistance can be acquired is presented.
Keywords: leptin,, obesity,, blood-brain barrier,, cerebrospinal fluid,, resistance,, transport
Current Pharmaceutical Design
Title: Is Obesity a Disease of the Blood-Brain Barrier? Physiological, Pathological, and Evolutionary Considerations
Volume: 9 Issue: 10
Author(s): William A. Banks
Affiliation:
Keywords: leptin,, obesity,, blood-brain barrier,, cerebrospinal fluid,, resistance,, transport
Abstract: Leptin has emerged as a major regulator of body adiposity. The majority of humans with obesity have a resistance to leptin. Human and rodent studies indicate that the major cause of this resistance arises from an impaired ability of leptin to cross the blood-brain barrier, with lesser roles played by receptor and post-receptor defects. Evidence from baboons living in the wild is consistent with the hypothesis that during most of evolution serum levels of leptin were much lower than those currently considered normal. Leptin may have evolved to signal to the brain when caloric reserves were adequate to engage in reproductive and other behaviors not immediately concerned with acquisition of calories. The leptin transporter is a regulated system, with the rate of transport being increased by alpha-1 adrenergic agents and decreased by starvation. Impaired regulation of the transporter or impairments in transporter production could underlie the resistance caused by transporter defects. Evolutionary pressures would not have selected against such impairments if leptin levels were lower than those typically seen in Western society. A model that could explain how leptin transporter resistance can be acquired is presented.
Export Options
About this article
Cite this article as:
Banks A. William, Is Obesity a Disease of the Blood-Brain Barrier? Physiological, Pathological, and Evolutionary Considerations, Current Pharmaceutical Design 2003; 9 (10) . https://dx.doi.org/10.2174/1381612033455350
DOI https://dx.doi.org/10.2174/1381612033455350 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Kruppel-Like Factor 2 (KLF2) Regulates Monocyte Differentiation and Functions in mBSA and IL-1β-Induced Arthritis
Current Molecular Medicine Towards Practical Cognitive Assessment for Detection of Early Dementia: A 30-Minute Computerized Battery Discriminates as Well as Longer Testing
Current Alzheimer Research Targeting Sphingosine-1-Phosphate Receptors in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Effects of Fusion Structure on the Expression and Bioactivity of Human Brain Natriuretic Peptide (BNP) Albumin Fusion Proteins
Current Pharmaceutical Biotechnology Bioenergetics Pathways and Therapeutic Resistance in Gliomas: Emerging Role of Mitochondria
Current Pharmaceutical Design Flaxseed and Diabetes
Current Pharmaceutical Design Targeting MCP-1 to Reduce Vascular Complications of Obesity
Recent Patents on Cardiovascular Drug Discovery Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Is Helicobacter pylori Always a "Bad Guy"?
Current Pharmaceutical Design The Potential of Microalgae for the Production of Bioactive Molecules of Pharmaceutical Interest
Current Pharmaceutical Biotechnology Recent Advances in Pulmonary Hypertension Therapy
Recent Patents on Cardiovascular Drug Discovery Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Should the Incorporation of Structural Alerts be Restricted in Drug Design? An Analysis of Structure-Toxicity Trends with Aniline-Based Drugs
Current Medicinal Chemistry Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Current Drug Safety Central and Peripheral Pain Generators in Women with Chronic Pelvic Pain: Patient Centered Assessment and Treatment
Current Rheumatology Reviews Tendinopathy and Neovascularization in Rheumatology
Current Rheumatology Reviews Role of C Reactive Protein (CRP) in Leptin Resistance
Current Pharmaceutical Design Nuclear Magnetic Resonance Spectroscopy and Genetic Disorders
Current Medicinal Chemistry Biologically Potent Pyrazoline Derivatives from Versatile (2)-1-(4- Chlorophenyl)-3-[4-(propan-2-yl)phenyl]prop-2-en-1-one
Letters in Drug Design & Discovery Microwave-assisted Extraction Coupled with High Performance Liquid Chromatography-electrospray Ion Trap Mass Spectrometry for the Determination of Three Flavone di-C-glycosides in Viola yedoensis
Current Analytical Chemistry